studies

squamous cell - mNSCLC - L1, atezolizumab plus carboplatin plus nab-paclitaxel vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-131 (ACnP), 2020 0.88 [0.73; 1.06] 0.88[0.73; 1.06]IMpower-131 (ACnP), 202010%683NAnot evaluable progression or deaths (PFS)detailed resultsIMpower-131 (ACnP), 2020 0.71 [0.60; 0.85] 0.71[0.60; 0.85]IMpower-131 (ACnP), 202010%683NAnot evaluable DORdetailed resultsIMpower-131 (ACnP), 2020 2.14 [1.13; 4.04] 2.14[1.13; 4.04]IMpower-131 (ACnP), 202010%309NAnot evaluable objective responses (ORR)detailed resultsIMpower-131 (ACnP), 2020 1.42 [1.05; 1.92] 1.42[1.05; 1.92]IMpower-131 (ACnP), 202010%683NAnot evaluable AE (any grade)detailed resultsIMpower-131 (ACnP), 2020 5.12 [1.11; 23.56] 5.12[1.11; 23.56]IMpower-131 (ACnP), 202010%668NAnot evaluable AE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.37 [0.98; 1.90] 1.37[0.98; 1.90]IMpower-131 (ACnP), 202010%668NAnot evaluable AE leading to death (grade 5)detailed resultsIMpower-131 (ACnP), 2020 2.59 [1.36; 4.92] 2.59[1.36; 4.92]IMpower-131 (ACnP), 202010%668NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpower-131 (ACnP), 2020 2.09 [1.45; 3.02] 2.09[1.45; 3.02]IMpower-131 (ACnP), 202010%668NAnot evaluable SAE (any grade)detailed resultsIMpower-131 (ACnP), 2020 2.28 [1.66; 3.14] 2.28[1.66; 3.14]IMpower-131 (ACnP), 202010%668NAnot evaluable STRAE (any grade)detailed resultsIMpower-131 (ACnP), 2020 2.27 [1.46; 3.51] 2.27[1.46; 3.51]IMpower-131 (ACnP), 202010%668NAnot evaluable TRAE (any grade)detailed resultsIMpower-131 (ACnP), 2020 1.80 [0.98; 3.28] 1.80[0.98; 3.28]IMpower-131 (ACnP), 202010%668NAnot evaluable TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.57 [1.14; 2.15] 1.57[1.14; 2.15]IMpower-131 (ACnP), 202010%668NAnot evaluable TRAE leading to death (grade 5)detailed resultsIMpower-131 (ACnP), 2020 1.34 [0.30; 6.02] 1.34[0.30; 6.02]IMpower-131 (ACnP), 202010%668NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.00 [0.07; 59.91] 2.00[0.07; 59.91]IMpower-131 (ACnP), 202010%668NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.09 [0.76; 1.58] 1.09[0.76; 1.58]IMpower-131 (ACnP), 202010%668NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 0.77 [0.28; 2.10] 0.77[0.28; 2.10]IMpower-131 (ACnP), 202010%668NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 8.08 [0.43; 153.53] 8.08[0.43; 153.53]IMpower-131 (ACnP), 202010%668NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 0.50 [0.02; 14.93] 0.50[0.02; 14.93]IMpower-131 (ACnP), 202010%668NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 3.41 [0.93; 12.49] 3.41[0.93; 12.49]IMpower-131 (ACnP), 202010%668NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 6.05 [0.30; 121.16] 6.05[0.30; 121.16]IMpower-131 (ACnP), 202010%668NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.44 [0.54; 3.83] 1.44[0.54; 3.83]IMpower-131 (ACnP), 202010%668NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.89 [0.75; 4.80] 1.89[0.75; 4.80]IMpower-131 (ACnP), 202010%668NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.66 [1.10; 6.46] 2.66[1.10; 6.46]IMpower-131 (ACnP), 202010%668NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.06; 16.05] 1.00[0.06; 16.05]IMpower-131 (ACnP), 202010%668NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.00 [0.07; 59.91] 2.00[0.07; 59.91]IMpower-131 (ACnP), 202010%668NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 4.02 [0.18; 89.44] 4.02[0.18; 89.44]IMpower-131 (ACnP), 202010%668NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.46 [0.72; 2.93] 1.46[0.72; 2.93]IMpower-131 (ACnP), 202010%668NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 3.55 [0.73; 17.23] 3.55[0.73; 17.23]IMpower-131 (ACnP), 202010%668NAnot evaluable Nephritis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 0.93 [0.65; 1.35] 0.93[0.65; 1.35]IMpower-131 (ACnP), 202010%668NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.00 [0.07; 59.91] 2.00[0.07; 59.91]IMpower-131 (ACnP), 202010%668NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.01 [0.37; 11.06] 2.01[0.37; 11.06]IMpower-131 (ACnP), 202010%668NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 4.04 [0.45; 36.31] 4.04[0.45; 36.31]IMpower-131 (ACnP), 202010%668NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.68 [0.40; 7.07] 1.68[0.40; 7.07]IMpower-131 (ACnP), 202010%668NAnot evaluable Rash TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 2.01 [0.18; 22.23] 2.01[0.18; 22.23]IMpower-131 (ACnP), 202010%668NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.00 [0.02; 50.55] 1.00[0.02; 50.55]IMpower-131 (ACnP), 202010%668NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 1.16 [0.68; 2.00] 1.16[0.68; 2.00]IMpower-131 (ACnP), 202010%668NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsIMpower-131 (ACnP), 2020 3.02 [0.31; 29.16] 3.02[0.31; 29.16]IMpower-131 (ACnP), 202010%668NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:23 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 308,164,166,220 - treatments: 865